TrialJournal of managed care & specialty pharmacy2026

Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation.

Santosh Gautam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.